Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- Safety of palonosetron administered for control of nausea and vomiting in patients with
metastatic melanoma receiving biochemotherapy.
- To determine the patterns and severity of nausea and vomiting in two groups of patients
with metastatic melanoma receiving biochemotherapy with palonosetron premedication using
two schedules of palonosetron administration.